ArticleOrphanet journal of rare diseases2026
Prospective pilot safety, feasibility study of an optic-to-audio device for children with CLN3 disease.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04974307 (Pilot Study of an Optic-to-Audio Device in a Pediatric Cohort With CLN3-related Conditions or Low Vision), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pilot Study of an Optic-to-Audio Device in a Pediatric Cohort With CLN3-related Conditions or Low Vision
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundLow-vision rehabilitative support for children with multiple-disability conditions is underexplored. We conduct a pilot study of an assistive device in children with CLN3 disease, a multisystemic pediatric blindness and neurodegenerative condition. The prospective, pilot study (NCT04974307) evaluated the safety, feasibility and preliminary efficacy of the OrCam MyEye 2 in aiding daily living tasks. We used multimodal assessments of feasibility and efficacy to assess nine participants with CLN3 disease and one with non-CLN3 low vision (age 8.1-17.4 years; females:males 2:8) at baseline (Day 1, without the device) and Day 5 (with the device).
resultsSurveyed parents and affected children reported desire for future research addressing the vision loss in CLN3 disease, and lower quality of life in vision-related domains. One grade 1 adverse event was recorded during the study. Feasibility and Function assessments showed that > 90% of evaluable participants scored above thresholds on feasibility assessments and > 25% had improved scores and performance time on device-specific tasks.
conclusionsThe data provide indications for the safety, feasibility and task-specific efficacy for the OrCam MyEye 2. They support further, including longitudinal, evaluation and consideration of such optic-to-audio devices as part of the toolbox for low vision therapy for children with multiple disabilities such as CLN3 disease.
trial registrationclinicaltrials.gov, NCT04974307. Registered 23 July 2021, https//clinicaltrials.gov/study/NCT04974307 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.